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Abstract
Purpose of Review Long-term survival has increased significantly in breast cancer patients, and cardiovascular side effects are
surpassing cancer-related mortality. We summarize risk factors, prevention strategies, detection, and management of
cardiotoxicity, with focus on left ventricular dysfunction and heart failure, during breast cancer treatment.
Recent Findings Baseline treatment of cardiovascular risk factors is recommended. Anthracycline and trastuzumab treatment con-
stitute a substantial risk of developing cardiotoxicity. There is growing evidence that this can be treated with beta blockers and
angiotensin antagonists. Early detection of cardiotoxicity with cardiac imaging and circulating cardiovascular biomarkers is currently
evaluated in clinical trials. Chest wall irradiation accelerates atherosclerotic processes and induces fibrosis. Immune checkpoint
inhibitors require consideration for surveillance due to a small risk of severe myocarditis. Cyclin-dependent kinases4/6 inhibitors,
cyclophosphamide, taxanes, tyrosine kinase inhibitors, and endocrine therapy have a lower-risk profile for cardiotoxicity.
Summary Preventive and management strategies to counteract cancer treatment–related left ventricular dysfunction or heart
failure in breast cancer patients should include a comprehensive cardiovascular risk assessment and individual clinical evaluation.
This should include both patient and treatment-related factors. Further clinical trials especially on early detection,
cardioprevention, and management are urgently needed.
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Introduction
Breast cancer is the leading cause of cancer in women world-
wide with a mean age standardized incidence of 46.3/100000,
ranging from 25.9 in South East Asia to 94.2 in Australia and
New Zeeland [1]. While the incidence is slightly increasing,
the mortality is decreasing, likely due to the effective screen-
ing programs and evolving treatment.
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Breast cancer treatment is based on the individual tumor’s
expression of specific markers as estrogen receptor (ER), pro-
gesterone receptor (PR), human epidermal growth factor re-
ceptor (HER) 2,the proliferation marker Ki-67, and the extent
of the disease. Combining surgery, chemotherapy, and radia-
tion therapy with targeted therapy, the outcome has improved
markedly over the past two decades and the average 5-year
survival is currently approximately 87% [1]. The prolonged
survival has led to an increased focus on the off-target-effects
of breast cancer treatment. In fact, cardiovascular complica-
tions may surpass cancer-related mortality in a subgroup of
patients [2]. Short-term acute left ventricular dysfunction, ar-
rhythmia, or ischemic events can hinder patients from receiv-
ing life-saving cancer treatment. The patients are also at risk of
developing long-term cardiovascular morbidity, especially de-
creased left ventricular function and heart failure. Heart failure
is associated with reduced quality of life and increased mor-
tality. In this article we summarize the clinically most relevant
risk factors for cardiovascular complications during breast
cancer therapy and discuss strategies for prevention, detection,
and management of cardiotoxicity. We will focus on left ven-
tricular dysfunction and heart failure.
Commonly Used Chemotherapy
Anthracyclines, i.e., epirubicin and doxorubicin, are among
the most widely used conventional chemotherapeutics
established in breast cancer treatment. Anthracyclines inhibit
deoxyribonucleic acid (DNA) synthesis and alters DNA tran-
scription and replication by intercalating DNA and ribonucle-
ic acid (RNA) strands and inhibiting topoisomerase IIα [3].
Anthracyclines also induce an iron-mediated oxidative stress
that damages DNA, proteins, and lipids [4]. Cardiomyocytes
and their mitochondria seem to be especially vulnerable to the
damage via inhibition of topoisomerase IIβ and increased
oxidative stress [5]. Dysregulation of epigenomic and
transcriptomic responses have also been reported [6].
Importantly, cardiotoxicity is a clinically dose-limiting ad-
verse effect of anthracyclines. In a retrospective report includ-
ing three randomized studies (doxorubicin/placebo), decom-
pensated congestive heart failure increased from 4.7% at
400 mg/m2 doxorubicin to 48% at doses of 650–800 mg/m2
[7]. About 50% of these patients had an absolute left ventric-
ular ejection fraction (LVEF) drop of more than 30%.
Importantly so, using sensitive echocardiographic methods
such as global longitudinal strain (GLS), early signs of
cardiotoxicity have been seen in doxorubicin doses as low as
150 mg/m2 [8]. Acute anthracycline-induced cardiotoxicity
occurs within a week from treatment and is rare (< 5%). It
resembles an acute toxic myocarditis with a histopathological
cardiomyocyte damage, inflammatory infiltration, and inter-
stitial edema [6, 9]. Often electrocardiographic (ECG)
changes are present with brady- or tachy-arrhythmias and clin-
ical symptoms as palpitations, dyspnea, chest pain, heart fail-
ure, syncope, or cardiac arrest. Chronic anthracycline-induced
cardiotoxicity is histopathological typically characterized by
vacuole formation, necrosis, myofibril dropout, and fibrosis
[9]. By echocardiography this can be seen as a drop in LVEF
or GLS. A decline in LVEF of ≥ 10 percentage to a value
below 50% is widely accepted to be of significance [10].
Typical risk factors for anthracycline-induced cardiotoxicity
are age < 5 or > 65 years, a family history of premature car-
diovascular disease, arterial hypertension, diabetes mellitus,
hypercholesterolemia, current myocardial disease, prior radi-
ation to chest or mediastinum, smoking, and obesity [11,
12••].
In conclusion, anthracyclines are a major cause of cancer
treatment-related cardiotoxicity in breast cancer patients.
Cyclophosphamide is an alkylating agent that in breast
cancer patients usually is combined with anthracyclines and
taxanes in the adjuvant setting. The cardiotoxicity is described
as ECG changes, left ventricular dysfunction, and heart fail-
ure. There is conflicting evidence about the incidence, and
numbers vary from < 1 to 28% [13]. In the standard adjuvant
regimen for breast cancer 600 mg/m2, cyclophosphamide is
given 3–4 times with 3-week interval. Recently, a dose-
escalating phase III trial tested intensified treatment with cy-
clophosphamide, in myeloma patients, with doses up to
500 mg orally day 1, 8, 15, and 3 weekly cycles until maxi-
mum response or intolerance. In total, 4 patients (< 1%) had
cardiac disorders, and this was not further specified [14]. In
conclusion, the results support the low-risk profile for cardiac
morbidity using cyclophosphamide in modern breast cancer
treatment.
Taxanes are agents inhibiting mitotic activity, and the
most frequently used drugs are docetaxel and paclitaxel.
Taxanes can be used as monotherapy or combined with
other chemotherapeutics including trastuzumab and
pertuzumab. Cardiotoxicity with taxanes is infrequent.
Reports are conflicting as the cardiotoxic definition is in-
consistent, including asymptomatic bradycardia to ische-
mic events [15]. Additionally, it has been debated whether
concomitant use of paclitaxel and doxorubicin aggravate
doxorubicin induced cardiotoxicity [16, 17]. The incidence
of docetaxel associated heart failure is < 2% [16, 18]. The
incidence of myocardial ischemia has only been reported in
the drugs summary of product characteristics (SPC) [19].
In a Cochrane review of taxanes for adjuvant treatment of
early breast cancer twenty three studies included data on
cardiotoxicity [20]. Pooled analysis showed small to no
difference in cardiotoxicity of taxane compared with non-
taxane-containing cancer treatment regimens (OR 0.87,
95% CI 0.56–1.33). Additionally, there was no difference
in the risk of cardiotoxicity comparing those with or with-
out anthracycline treatment (HR 1.27, 95% CI 0.88 to
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Endocrine therapy is a corner stone in the treatment of hor-
mone receptor positive breast cancer subtypes (ER/PR posi-
tive). In the adjuvant setting, endocrine therapy is given to
selected patients for 5 to 10 years. Estrogen has indirect and
direct effects on the cardiovascular system through the serum
lipoprotein metabolism, coagulation, and fibrinolytic systems,
and the antioxidative capacity. There have been concerns that
estrogen inhibition in breast cancer treatment might mimic the
postmenopausal effect on the cardiovascular system resulting
in worsened cardiovascular outcome [21]. In breast cancer
patients, antihormonal therapy is based on two major strate-
gies, ER-modulators or inhibition of estrogen synthesis.
Modulation of the ER is performed with selective ER modu-
lators as tamoxifen, or estrogen receptor down-regulators as
fulvestrant. The last two decades have been dominated by the
introduction of aromatase inhibitors for postmenopausal
women, inhibiting estrogen synthesis, i.e., with anastrozole,
letrozole, and exemestane. Tamoxifen has shown to exert pos-
itive effects on the blood lipid profiles [22] and is believed to
have a favorable cardiovascular effect [23], but its thrombo-
embolic effect needs to be taken into consideration [24].
Aromatase inhibitors have been compared with placebo in
several trials and do not seem to increase the risk for cardio-
vascular events in a significant manner [22]. However, these
studies are not powered for cardiac events and frequently do
not report specific cardiovascular adverse events. Aromatase
inhibitors, when compared with tamoxifen, show an increased
risk of arterial events as myocardial infarction and angina,
which must be interpreted in the context of the protective
effect of tamoxifen [22, 25]. Tamoxifen is primarily given to
premenopausal women, while aromatase inhibitors of the
third generation, i.e., anastrozole, letrozole and exemestane,
are used in postmenopausal women.
Mammalian target of rapamycin (mTOR) inhibitors may be
used in combination with exemestane in selected postmeno-
pausal breast cancer patients with metastatic disease and have
shown improved progression free survival compared with
exemestane alone [26, 27]. mTORs can exhibit an indirect effect
on cardiovascular health by metabolic changes, i.e., glucose and
lipid metabolism, but are generally well tolerated [28]. Overall,
the cardiovascular tolerability of endocrine therapy is high.
HER2 Targeted Drugs
Approximately 15% of breast cancers are HER2 positive and
are associated with aggressive behavior of the tumor [29].
Trastuzumab, a humanized monoclonal antibody against the
extracellular domain of HER2, is in breast cancer often used
in combination with chemotherapy or endocrine treatment [30,
31]. Pertuzumab is a recombinant humanized monoclonal an-
tibody that binds to the extracellular domain of HER2 and
functions as a dimerization inhibitor. As pertuzumab and
trastuzumab binds to different domains of the HER2, a combi-
nation therapy is more beneficial than trastuzumab alone [32].
The HER2 receptor (also known as ERBB2 receptor) is
expressed on cardiomyocytes, where it is involved in intracel-
lular signaling pathways controlling apoptosis, cell regenera-
tion, and to some extent the contractile function [33].
Blocking HER2 by trastuzumab may cause left ventricular
dysfunction [32], but the complete mechanism of
trastuzumab-induced cardiotoxicity is still not fully under-
stood. In the clinical setting trastuzumab-induced myocardial
dysfunction is potentiated by prior treatment with
anthracyclines, which is also supported by preclinical studies
[34–37]. Other risk factors include age > 65 years, high body
mass index > 30 kg/m2, hypertension, and lower LVEF at
baseline, while there are still conflicting data on other cardio-
vascular risk factors as diabetes, coronary artery disease, val-
vular dysfunction, and left ventricular hypertrophy [34, 38].
Trastuzumab-induced left ventricular dysfunction is to some
extent reversible when paused or discontinued [10, 39–41].
Other studies have shown a persistent reduction in the left
ventricular function after trastuzumab cessation [42–44]. In a
study with 251 HER2 positive breast cancer patients, 42 pa-
tients had a LVEF drop of > 10% unit to a value below 50%,
and 40% of these patients did not regain full cardiac function
after enalapril and carvedilol treatment [42]. Whether this ir-
reversibility is due to concomitant anthracycline toxicity is
still unclear. The clinical presentation ranges from asymptom-
atic impaired left ventricular function to fulminant heart fail-
ure [32, 41]. In 2012 a Cochrane report based on randomized
controlled trials of adjuvant therapy in breast cancer, the range
of left ventricular dysfunction was between 7 and 34%. The
rate of clinical severe heart failure (New York Heart
Association (NYHA) class III or IV) ranged between 0 and
4% [45]. The risk is higher in older patients. In a register study
identifying more than 45,000 patients over 67 years and treat-
ed with adjuvant therapy for early breast cancer, the adjusted
3 year incidence of heart failure or left ventricular dysfunction
was 31% for those treated with trastuzumab alone, 42% for
those treated with trastuzumab and anthracycline, and 18% for
patients without adjuvant therapy [46]. Dual therapy with
trastuzumab and pertuzumab does not increase the risk of
cardiotoxicity compared with trastuzumab alone [47, 48].
The tyrosine kinase inhibitors lapatinib and tucatinib are
approved for the treatment of HER2-positive, trastuzumab-
resistant metastatic breast cancer [49, 50]. Neratinib is in some
countries approved for extended adjuvant treatment [51]. In
clinical trials the risk of cardiotoxicity of these drugs are lower
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than for trastuzumab; however, these trials included a low risk
cohort [50, 52, 53] .
In conclusion, anti-HER2 therapy with trastuzumab is as-
sociated with significant risk of developing cardiotoxicity.
There is no evidence of increased risk of cardiotoxicity when
pertuzumab is added to trastuzumab.
CDK 4/6 Inhibitors
Dysregulation of the cyclin-dependent kinases (CDK) 4/6–cy-
clin-D cell-cycle pathway induces a loss of mitotic regulation
[54] and is associated with endocrine resistance in breast cancer
[55]. Small-molecule CDK4/6-inhibitors as ribociclib,
palbociclib, and abemaciclib have shown the ability to inhibit
the growth of ER–positive breast cancer cells, act synergistically
with antiestrogens, and reverse endocrine resistance [55–58].
CDK4/6 inhibitors with either aromatase inhibitors or antiestro-
gens are currently recommended as first-line treatment option
for metastatic ER-positive and HER2-negative breast cancers
[49]. Regarding cardiac safety, a range of different cardiovascu-
lar toxicities has been reported. Moderate QT prolongation has
been observed with ribociclib, and ECG monitoring is advised
[57]. In addition, the risk of venous thromboembolic events is
increased compared with endocrine treatment only [55, 57]. In
cell models and rodents, the CD4 activation pathway is impor-
tant in early cardiomyocyte remodeling after myocardial infarc-
tion [59]; however, the clinical significance of this is unclear.
ICI
The use of immune checkpoint inhibitors (ICIs) has vastly
improved clinical outcomes in several cancer types during
the last decade. However, in breast cancer patients the effect
of current ICI regimens has been less beneficial [60].
Atetzolizumab and pembrolizumab have been approved for
breast cancer treatment [61, 62]. As ICIs improve the activity
of cytotoxic T-lymphocytes through blocking a major inhibi-
tory pathway, these drugs may also cause a number of
immune-related adverse events [63]. A feared but rare ICI-
related adverse event is myocarditis, which may be associated
with mortality rates up to 50% [64, 65]. Other rare ICI-
mediated cardiovascular toxicities are pericarditis, heart block,
acute coronary syndromes, Takotsubo syndrome, and during
longer treatment non-inflammatory heart failure [66]. The use
of ICI is expected to increase, and the cardiovascular compli-
cations will be an important issue for further surveillance.
Radiation Therapy
The aim of radiation therapy may be curative, adjuvant, or
palliative, and most patients receive radiation as part of a
multimodal treatment strategy including surgery, chemother-
apy, and targeted therapies. For most patients the gains of
improved survival and organ-preservation outweigh the risks
of normal tissue effects as fibrosis, necrosis, and pain. Serious
life-threatening late effects as heart disease and secondary
cancers are uncommon. Radiation-associated heart disease
usually materializes more than a decade after treatment [67].
With improved cancer survival, more patients are at risk of
suffering from radiation-associated heart disease.
Both the micro- and the macro- coronary circulation and
the left sided cardiac valves can be affected. In breast cancer
patients a dose–response relationship between radiation dose
to the heart and risk of major coronary events or cardiac death
was established. A relative risk of major coronary events or
heart death increased by 7.4% per 1 Gy increases in mean
heart dose. Importantly, there was no lower safe dose [68].
Pre-existing vascular disease may increase the risk of cardiac
complications [69]. Radiation-associated heart disease has
shown to be more lethal compared with heart disease not
related to radiation [70]. Rarely, the radiation effect on the
heart may occur acutely or subacutely (pericarditis and/or
myocarditis), but usually, the effect occurs within 10 years
in women with pre-existing coronary disease and 10+ years
in lower risk individuals where healthy coronary vessels were
exposed to radiation. Restrictive cardiomyopathy or constric-
tive pericarditis represents an advanced stage of damage due
to fibrosis of the myocardium or pericardium with severe di-
astolic dysfunction and signs and symptoms of congestive
heart failure [67, 71]. In conclusion radiation-induced cardiac
disease may present decades after treatment completion.
Detection
Imaging
Cardiac dysfunction secondary to cancer treatment can be de-
fined as an absolute drop in LVEF of ≥ 10% to a value below
< 50% [10]. Nuclear multigated acquisition (MUGA) and echo-
cardiography are the most common modalities for serial LVEF
measurements. A significant decline in LVEF might influence
the continuation of cancer treatment; hence, LVEF measure-
ments should be repeated after 2–3 weeks to confirm the decline
[72]. The method of choice and vendor should preferably be
consistent through the surveillance period and adapted to local
availability and expertise (Table 1). LVEF comparison between
different modalities is not advisable. If possible, MUGA should
be avoided mainly due to radiation exposure [10]. Cardiac mag-
netic resonance imaging (CMR) is a reliable method for assess-
ment of cardiac function and is the gold standard to measure
volumes and EF. CMR adds value in differential tissue diagnos-
tics; however, its unavailability and high cost precludes a more
general use. As new cancer therapy-induced adverse effects
arise, the role of CMR may become more prominent. ICI-
mediated perimyocarditis might be missed by simple LVEF
measurement; instead, it should be examined by CMR with
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T1 and T2 mapping to detect myocardial edema along with late
gadolinium contrast enhancement of the inflamed pericardium
and myocardium [73].
When using echocardiography, the most reliable mea-
surement of LVEF is the transthoracic three-dimensional
volumetric method. When not available, biplane Simpson
method from two-dimensional echocardiography should
be used. Two-dimensional GLS measured using speckle
tracking is a more sensitive method than LVEF to evalu-
ate early changes in left ventricular systolic function and
should be used together with LVEF [10, 12•, 72]. It has
been suggested that a GLS value of <18% or a relative
reduction of 15% from baseline is significant [12•, 72].
However, these thresholds are based on small observa-
tional studies. It is unconfirmed if early change in GLS
values will predict persistent decrease in LVEF or the
development of systolic heart failure. Results from the
SUCCOUR (Strain sUrveillance of Chemotherapy for im-
proving Cardiovascular Outcomes) study, a randomized
controlled international multicenter trial of GLS and EF
in surveillance of cardiotoxicity in cancer patient, is high-
ly awaited [74]. The target inclusion is 320 patients with a
follow-up time of 3 years. The results will hopefully pro-
vide evidence for whether the use of GLS for surveillance
for cardiotoxicity improves clinical outcomes.
Other sensitivemethods tomeasure cardiotoxicity, as changes
in right heart function, diastolic function, and changes unveiled
during exercise, are in their infancy regarding to their reliability,
usability and overall clinical relevance [12••, 72, 75, 76].
Echocardiographic Follow-Up During Treatment with
Anthracycline and Trastuzumab
Routine cardiac surveillance under anthracycline and
HER2-treament has been recommended by both the
cardiology and oncology working groups [10, 12••,
77••]. Expert consensus papers argue that baseline cardiac
function should be assessed before adjuvant anthracycline
treatment, especially as part of baseline risk assessment
[10, 72, 76, 77••, 78].
Anthracyclines
A baseline cardiac evaluation is desirable in all patients
scheduled to receive anthracycline chemotherapy using
the new Heart Failure Association of the European
Society of Cardiology in collaboration with the
International Cardio-Oncology Society (HFA-ICOS) base-
line risk stratification proforma [79••]. Based on the ac-
cumulated dose-dependent toxicity of anthracyclines,
follow-up is recommended, especially when cumulative
doxorubicin-doses exceeds 240 mg/m2 [10, 77••]. These
strategies have not been validated to prevent long-term
cardiac events, nor has long-term follow-up after comple-
tion of anthracycline-therapy.
Trastuzumab
For HER2-targeted therapies, a baseline measurement of
cardiac function by LVEF and GLS is suggested using the
new HFA-ICOS baseline risk stratification proforma
[79••]. According to The Food and Drug Administration
(FDA) approval, serial cardiac evaluation during
trastuzumab treatment should be performed every 3rd
month. This is based on clinical trial protocols.
However, this ‘one size fits all’ approach is not logical
clinically, and a more personalized monitoring schedule
based upon baseline risk has been suggested [79••]. Even
though frequent cardiac surveillance are recommended








Echo, 2D LVEF, biplane
Simpson
> 53% ≥ 10% absolute
change to a value
<50%
Widely accessible and used, but relatively
high variability
Recommended in combination
with GLS and biomarkers
Echo, speckle
tracking
GLS > 18% value <18% or > 15%
relative reduction
from baseline
High reliability and validity, sensitive for early
detection, especially in combination with
biomarkers.
Recommended in combination
with 2D echo and biomarkers
Echo, 3D LVEF, 3D > 55% ≥ 10% absolute
change to a value
< 50%
High reliability, not so widely used, more
complicated than 2D
Recommended if available
CMR LVEF > 55% ≥ 10% absolute
change to a value
< 50%
Reliable method, low availability, add tissue
information when needed
Recommended when tissue
information is necessary (i.e.,
myocarditis)
CMR cardiac magnetic resonance imaging, Echo echocardiography, GLS global longitudinal strain, LVEF left ventricular ejection fraction
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[12••], studies on the optimal frequency of cardiac moni-
toring during trastuzumab treatment are lacking [80].
Biomarkers
Serum cardiac biomarkers indicating cardiac injury or dys-
function can be considered incorporated to the surveillance
of patient at risk of cardiotoxicity. Even though a wide
selection of different biomarkers has been studied, B-type
natriuretic peptides (BNP) and cardiac troponins have been
adopted to clinical practice. The value of BNP to detect
cancer treatment related cardiotoxicity is limited by other
variables that influence their levels including hemodynam-
ic changes from stress, hypertension, infusions, vomiting,
diarrhea, etc. A markedly elevated level of BNP has a high
sensitivity for heart failure, while the specificity is variable
[81]. It is unclear whether a rise in BNP precedes a decline
in LVEF during breast cancer treatment [82]. Elevated
levels of BNP during radiation therapy has been demon-
strated, but the significance of this is unclear [83, 84].
While BNP is a marker of cardiac dysfunction, cardiac
troponins are markers of myocardial injury. A rise in car-
diac troponin I during high-dose anthracycline treatment
has been a strong predictor of later LVEF decline and clin-
ical events [85]. However, it is unclear if a rise in high
sensitivity troponin precedes a decline in LVEF in contem-
porary breast cancer treatment [82]. Recently, the
International CardioOncology Society-one trial (ICOS-
ONE) evaluated the hypothesis of biomarker-guided
cardioprotection versus primary prevention in 273 cancer
patients scheduled to receive anthracycline chemotherapy,
including breast cancer patients [86]. The results showed
that the incidence of new troponin elevation was 23–26%
in both arms. Enalapril pre-treatment in primary prevention
did not prevent the troponin elevation, but it did reduce
maladaptive remodeling and LV dysfunction in the very
few individuals who sustained a cardiac injury and tropo-
nin rise. This trial was limited by relatively small numbers,
variability of the troponin assays used in the recruitment
hospitals, a relatively low risk cohort, and 14% of patients
in the primary prevention arm stopping enalapril due to
side effects.
Previous guidelines recommend monitoring troponin in
high-r isk pat ients to guide the decis iveness of
cardioprotective management [10, 77••]. The most recent
position statement from the HFA-ICOS recommends mea-
surement at baseline pre-treatment to contribute to risk
assessment [79••].
An increase in cardiac troponin is one of the diagnostic
criteria for ICI-myocarditis [87]. Ideally, a cardiac tropo-
nin should be measured at baseline pre-treatment to place
any future values in context. The benefit of routine
cardiac troponin monitoring in all cancer patients receiv-
ing ICI without any cardiac symptoms is unclear.
Preventive and Management Strategies
Risk Factor Assessment
A pre-treatment cardiovascular risk assessment should be
made for all patients using the new HFA-ICOS baseline risk
stratification proformas to minimize the additional risk for
developing cardiovascular disease during cancer treatment,
i.e., evaluating baseline cardiac function, biomarkers, prior
cardiovascular disease, and cardiovascular risk factors includ-
ing glucose levels, lipid status, and checking blood pressure
[79••]. These factors should be treated according to guidelines
(Fig. 1). Beta blocker and/or an angiotensin antagonist should
be considered for the treatment of hypertension as these drugs
have shown additional cardioprotective effect during
anthracyclines and/or trastuzumab treatment [88–94].
Patients with established cardiovascular disease should be
on optimal treatment, and a recent echocardiogram is essential
to verify their cardiac function. A pre-existing diagnosis of
heart failure does not necessarily exclude treatment with
anthracyclines or trastuzumab but identifies high-risk patients.
A careful cardiac evaluation should determine the reason for
the heart failure, i.e., heart failure with reduced (HFrEF) or
preserved ejection fraction (HFpEF) or reversible causes, i.e.,
arrhythmia, coronary disease with ischemia, or Takotsubo
syndrome. Smaller studies are indicating that even those with
reduced or decline in LVEF may tolerate HER2-targeted ther-
apy under cardioprotective treatment and close cardiac moni-
toring [41, 95•, 96•]; however, larger studies are awaited to
confirm these findings.
Management of Left Ventricular Dysfunction
In standard heart failure care and prevention there is strong
evidence for symptom relief and mortality benefits for the
treatment of HFrEF (LVEF < 40%) [97]. Breast cancer pa-
tients presenting with HFrEF should receive standard heart
failure care according to guidelines. This includes both phar-
macological treatment as angiotensin antagonists, beta
blockers, mineral corticoid receptor antagonists (MRA),
sacubitril and ivabradine, and device treatment [81]. One
known side effect of MRA spironolactone is gynecomastia
due to peripheral conversion of testosterone to estradiol.
Several studies have studied the use of spironolactone, but
there has been no evidence of increased risk for breast cancer
[98]. There is no proven treatment for HFpEF (LVEF > 50%)
and heart failure with midrange ejection fraction (HFmrEF)
(LVEF between 40 and 50%). Although the evidence is not
strong, new studies support continuation of Trastuzumab if
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LVEF is > 40% in asymptomatic patients [95•, 96•]. If LVEF
drops ≥ 10% to a value < 50%, treatment with angiotensin
antagonists and beta blockers are recommended [10, 77••,
95•, 96•]. Some early preventive studies during trastuzumab
are more consistent with the protective effect of angiotensin
antagonists than beta blockers [88–90, 92]. Data are lacking of
when early cardioprotective treatment should be commenced,
it should be evaluated based on change in cardiac function,
elevated/rise in troponin and BNP, and cardiovascular comor-
bidities. Interestingly studies show that the use of beta
blockers may attenuate the rise in cardiac troponin during
anthracycline treatment, in none of these studies did beta
blocker treatment effect the LVEF [90, 99]. The true meaning
of mitigating the rise of troponin is unclear as long-term fol-
low-up data is missing.
Dexrazoxane is well documented as a cardioprotective
drug during anthracycline treatment [100]. Its use has been
subdued because of concerns that it may either reduce the
efficacy of anthracycline treatment against the primary malig-
nancy or increase the risk of second malignancies. However,
Cochrane Database Systemic Review analyses have shown no
long-term safety concerns [100].
Endocrine Treatment
Compared with placebo neither tamoxifen nor aromatase in-
hibitors increase the risk of myocardial infarction. There are
no studies comparing discontinuation–continuation of endo-
crine therapy if a cardiovascular event occurs.
Radiation Therapy
There is no evidence of cardioprotective treatment during ra-
diation therapy. Complications should be treated according to
general recommendations. However, it is important to keep in
mind that irrradiation may also damage the microvasculature
contributing to heart failure and that irrradiation often effects
the proximal parts of the coronary arteries causing fibrotic
lesions that are difficult to treat. Whether percutaneous coro-
nary intervention (PCI) on these lesions is related to more
complications is unclear [101, 102].
Immune Checkpoint Inhibitors
In patients with ICI-myocarditis early treatment with high-
dose intravenous methylprednisolone of 500–1000 mg i.v.
for 3 days is recommended. If improvement is seen, a switch
to oral prednisolone of 0.5–1 mg/kg with a weekly weaning
schedule can be made [66, 103•]. Delaying high-dose steroids
in cases of ICI-myocarditis increases the risk of major adverse
cardiac events including mortality [103•]. If the myocarditis
does not settle with high-dose methylprednisolone, second
line immunosuppressive drugs should be considered includ-
ing mycophenolate mofetil and possibly abatacept [104].
Fig. 1 Detection and management of heart failure in patients receiving
treatment for breast cancer. AA angiotensin antagonist, BB beta blocker,
CVD cardiovascular disease, ECG electrocardiographic, GLS global
longitudinal strain, HCA-ICOS Heart Failure Association of the
European Society of Cardiology in collaboration HFmEF heart failure
with midrange ejection fraction, HFrEF heart failure with reduced
ejection fraction, Hs-Troponin high sensitive troponine with the
International Cardio-Oncology Society, LDL low dense lipoprotein,
LVEF left ventricular ejection fraction, NT-proBNP B-type natriuretic
peptides
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Plasmapheresis can also be considered [105••, 106]. In asymp-
tomatic cases where elevated troponin levels are detected by
screening, oral prednisolone of 2 mg/kg/day may be consid-
ered [77••, 105••].
Conclusion
Modern breast cancer treatment is effective and has improved
long-term survival. However, the long-term cardiovascular
mortality and morbidity in these patients have also risen.
The risk of left ventricular dysfunction and heart failure is
substantially increased following treatment with anthracycline
and trastuzumab. Chest wall radiation accelerates the athero-
sclerotic process and induces fibrosis. Immune checkpoint
inhibitors are associated with fatal myocarditis. CDK4/6 in-
hibitors, cyclophosphamide, taxanes, tyrosine kinase inhibi-
tors, and endocrine therapy have a lower-risk profile for
cardiotoxicity.
Treatment of cardiovascular risk factors is recommended to
avoid cardiotoxicity. Echocardiography and measuring circu-
lating cardiovascular biomarkers such as troponins and BNP
are useful as baseline markers and in evaluating the deleteri-
ous effect cancer treatment may have on the heart. The fre-
quency of surveillance is based on expert consensus rather
than randomized trials. HFA Cardio-Oncology Study Group
has recently suggested a structured pathways for baseline risk
assessment and surveillance. Beta blockers and angiotensin
antagonists have shown promising results to prevent
cardiotoxicity during anthracycline and trastuzumab treat-
ment. Cardiopreventive techniques should be used in breast
radiotherapy to minimize the cardiac radiation dose. If ICI-
induced myocarditis is suspected, early intervention with high
dose methyl-prednisolone has shown promising results.
Further clinical trials focusing on early detection,
cardioprevention, and management are needed to elucidate
the best strategies to prevent short- and long term develop-
ment of left ventricular dysfunction and heart failure and thus
promoting overall survival and quality of life.
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